dcsimg

What is Prolia® (denosumab)?

Prolia® (denosumab) is indicated for the treatment of osteoporosis in postmenopausal women and in men who are at increased risk of fractures.1
During the menopause, oestrogen levels decrease, RANKL expression increases, and this subsequently leads to enhanced osteoclast formation, function and survival. Prolia® mimics the action of the naturally occurring protein osteoprotegerin (OPG) that inhibits and regulates RANK Ligand.1,2
In this way, Prolia® significantly reduces the risk of vertebral, non-vertebral and hip fractures in post menopausal women.1

References

  1. Prolia® (denosumab) Summary of Product Characteristics
  2. Baron R, et al. Bone 2011;48:677-692